{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-056130","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.756945+00:00","generated_at":"2026-06-25T23:33:54.068034+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ironwood Q1 2022: LINZESS Rx demand +11%; net sales $232M; GAAP net income $39M","bullets":["LINZESS U.S. net sales $232M (+8% YoY); prescription demand growth +11% YoY.","Total revenue $98M; GAAP net income $39M ($0.21 diluted EPS).","Adjusted EBITDA $58M, up from $46M; cash and equivalents $593M.","Full-year 2022 financial guidance reaffirmed; LINZESS exceeded $1B in 2021.","CEO cites progress in clinical trials and plans to in-license or acquire GI assets."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-056130","json":"https://secwatch.observer/filing/0001104659-22-056130.json","markdown":"https://secwatch.observer/filing/0001104659-22-056130.md","text":"https://secwatch.observer/filing/0001104659-22-056130.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465922056130/0001104659-22-056130-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465922056130/tm2214395d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:33:54.068034+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}